Movement Alert｜Natera Falls 3.33% in Regular Trading, Profit-Taking Extends After Melanoma Study Launch

Market Focus10-08

On October 8, Natera fell 3.33% in regular trading, trading at $382.25 per share, with turnover of $114 million.

The decline extends profit-taking pressure following the company's announcement of a clinical study with NYU Langone Health for its Signatera test in advanced melanoma. Investors have been locking in gains after a prior rally sparked by the launch of a phase 3 breast cancer trial.

The new melanoma study will use Signatera to detect persistent molecular residual disease before radiographic progression, aiming to guide treatment escalation for patients with advanced or metastatic melanoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment